Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to embed the company’s AI platform into scientific instruments and lab workflows, aiming to accelerate automation, analytics and instrument intelligence. The partnership will pair Thermo Fisher’s instrument base with NVIDIA’s DGX and BioNeMo models to scale lab‑in‑the‑loop capabilities. Separately, NVIDIA and Eli Lilly revealed a $1 billion co‑innovation lab to apply BioNeMo and advanced AI to drug discovery, connecting wet lab efforts to in‑silico design. Both moves underscore deepening ties between large tech AI platforms and life‑science companies to compress discovery timelines and augment laboratory throughput.